The joint study will look to quantify the level of increased perfusion and oxygenation during and after treatment with the DermaPace, Suwanee, Ga.-based Sanuwave said. The study will use HyperMed’s Hyperview spectral imaging device to measure oxygen saturation, oxyhemoglobin levels and deoxyhemoglobin levesl in superficial tissue.
Sanuwave said that an initial case series in the study will be performed at two sites, Newark, N.J.’s Rutgers NJMs University Hospital Vascular and Wound Care Center and UCLA Medical Center Olive View. Dr. Oscar Alvarez will act as principal investigator at Rutgers, while Dr. Aksone Nouvong will lead efforts at UCLA.
“We are very excited about this next opportunity to investigate the effects that the DermaPace system has on improving perfusion and oxygenation in treated tissue. This case series will enable us to quantify the increases and help us to better understand how DermaPace improves patients’ quality of life, leading to future research and improvement of clinical protocols for the treatment of diabetic foot ulcers and other skin conditions. We are another step closer to Healing Today, Curing Tomorrow,” Sanuwave CEO Kevin Richardson II said in a press release.
Last month, Sanuwave said it entered a memorandum of understanding with eKare to develop novel wound care analysis and management solutions which integrates technology from both companies.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.